First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II

被引：0
|
作者：
Delord, Jean-Pierre [1 ]
Bennouna, Jaafar [2 ]
Dieras, Veronique [3 ]
Campone, Mario [2 ]
Lefresne, Florence [4 ]
Aslanis, Vassili [5 ]
Douillard, Jean-Yves [2 ]
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Rene Gauducheau, F-44035 Nantes, France
[3] Inst Curie, Paris, France
[4] Inst Rech Pierre Fabre, Boulogne, France
[5] Inst Rech Pierre Fabre, Castres, France
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3380S / 3380S
页数：1
相关论文
共 50 条
  • [31] First synthesis of subelliptenone F, an inhibitor of topoisomerase II
    Ohira, S
    Fukamachi, N
    Nakagawa, O
    Yamada, M
    Nozaki, H
    Iinuma, M
    CHEMISTRY LETTERS, 2000, (05) : 464 - 465
  • [32] Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients
    Abigerges, D
    Armand, JP
    Chabot, GG
    Bruno, R
    Bissery, MC
    Bayssas, M
    KlinkAlakl, M
    Clavel, M
    Catimel, G
    ANTI-CANCER DRUGS, 1996, 7 (02) : 166 - 174
  • [33] Blood purification device completes first-in-man study
    不详
    EXPERT REVIEW OF MEDICAL DEVICES, 2009, 6 (02) : 112 - 112
  • [34] The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects
    Nagelschmitz, Johannes
    Becka, Michael
    Kaufel, Dorina
    Schwers, Stephan
    von Nussbaum, Franz
    Li, Volkhart
    Wensing, Georg
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [35] Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects
    van Meer, Leonie
    van Dongen, Marloes
    Moerland, Matthijs
    de Kam, Marieke
    Cohen, Adam
    Burggraaf, Jacobus
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (01):
  • [36] First-in-man phase I study of PM01183 using an accelerated titration design
    Ratain, M. J.
    Elez, M. E.
    Szyldergemajn, S.
    Geary, D.
    Kang, S. P.
    Maraculla, T.
    Yovine, A.
    Soto-Matos, A.
    Tabernero, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 137 - 138
  • [37] Safety evaluation to support first-in-man investigations II: Toxicology studies
    Baldrick, Paul
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2008, 51 (02) : 237 - 243
  • [38] BERUBICIN: A NOVEL TOPOISOMERASE II INHIBITOR WITH ACTIVITY IN EPENDYMOMA
    Koul, Dimpy
    Fokt, Izabela
    Guan, Su
    Conrad, Charles A.
    Madden, Timothy
    Yung, W. K. Alfred
    Priebe, Waldemar
    NEURO-ONCOLOGY, 2009, 11 (05) : 640 - 640
  • [39] Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity
    Anthony, S. P.
    Read, W.
    Rosen, P. J.
    Tibes, R.
    Park, D.
    Everton, D.
    Tseng, B.
    Whisnant, J.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Sequential topotecan (topoisomerase I inhibitor) and etoposide (topoisomerase II inhibitor) in advanced, adult solid tumours
    Watson, JV
    Bulusu, VR
    Deary, A
    BRITISH JOURNAL OF CANCER, 1998, 78 : 34 - 34
12345